Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative medications operate by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these agents increase insulin secretion and

The burgeoning landscape of innovative treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight reduction – they exhibit intriguing contrasts in their